Cardiff’s Move Into First-Line mCRC Backed By Data From Discontinued Study

 
• By Joseph Haas
  
Metastatic cancer
Cardiff is working to develop the first new therapy for first-line mCRC in 20 years • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D